Xponance Inc. decreased its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 1.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 328,166 shares of the company’s stock after selling 4,541 shares during the quarter. Johnson & Johnson accounts for 0.7% of Xponance Inc.’s portfolio, making the stock its 16th largest position. Xponance Inc.’s holdings in Johnson & Johnson were worth $54,318,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently made changes to their positions in JNJ. Peak Asset Management LLC increased its holdings in shares of Johnson & Johnson by 9.3% in the 1st quarter. Peak Asset Management LLC now owns 13,789 shares of the company’s stock worth $2,137,000 after purchasing an additional 1,171 shares in the last quarter. Nisa Investment Advisors LLC boosted its position in shares of Johnson & Johnson by 0.9% during the first quarter. Nisa Investment Advisors LLC now owns 748,842 shares of the company’s stock valued at $116,071,000 after buying an additional 6,836 shares during the last quarter. Vaughan Nelson Investment Management L.P. increased its holdings in Johnson & Johnson by 21.8% in the 1st quarter. Vaughan Nelson Investment Management L.P. now owns 903,546 shares of the company’s stock worth $140,050,000 after buying an additional 161,687 shares in the last quarter. Tekla Capital Management LLC raised its position in Johnson & Johnson by 12.8% in the 1st quarter. Tekla Capital Management LLC now owns 721,779 shares of the company’s stock worth $111,876,000 after buying an additional 82,100 shares during the last quarter. Finally, Wisconsin Capital Management LLC boosted its holdings in shares of Johnson & Johnson by 0.8% during the 1st quarter. Wisconsin Capital Management LLC now owns 15,723 shares of the company’s stock valued at $2,437,000 after acquiring an additional 127 shares during the last quarter. Institutional investors own 68.40% of the company’s stock.
Wall Street Analysts Forecast Growth
JNJ has been the topic of a number of research analyst reports. Morgan Stanley lowered their price objective on shares of Johnson & Johnson from $187.00 to $172.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 31st. Credit Suisse Group increased their price target on Johnson & Johnson from $170.00 to $175.00 and gave the company a “neutral” rating in a report on Friday, July 21st. Citigroup initiated coverage on Johnson & Johnson in a research report on Tuesday, May 30th. They set a “buy” rating and a $185.00 price objective for the company. Raymond James cut their target price on shares of Johnson & Johnson from $184.00 to $179.00 and set an “outperform” rating for the company in a research report on Tuesday, September 5th. Finally, TheStreet upgraded shares of Johnson & Johnson from a “c+” rating to a “b+” rating in a research report on Monday, August 21st. Nine equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Hold” and a consensus price target of $170.65.
Johnson & Johnson Trading Down 0.7 %
JNJ stock opened at $160.50 on Monday. The company has a market capitalization of $417.13 billion, a price-to-earnings ratio of 32.49, a PEG ratio of 3.25 and a beta of 0.54. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.12 and a quick ratio of 0.88. Johnson & Johnson has a 1-year low of $150.11 and a 1-year high of $181.04. The business has a 50 day simple moving average of $166.51 and a two-hundred day simple moving average of $162.06.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its earnings results on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, beating the consensus estimate of $2.62 by $0.18. The company had revenue of $25.53 billion during the quarter, compared to analysts’ expectations of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. Johnson & Johnson’s quarterly revenue was up 6.3% on a year-over-year basis. During the same period last year, the company posted $2.59 earnings per share. Research analysts anticipate that Johnson & Johnson will post 10.02 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Thursday, September 7th. Investors of record on Monday, August 28th were paid a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a yield of 2.97%. The ex-dividend date was Friday, August 25th. Johnson & Johnson’s payout ratio is presently 96.36%.
Insider Buying and Selling at Johnson & Johnson
In other news, insider William Hait sold 14,698 shares of the stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the completion of the transaction, the insider now directly owns 87,747 shares in the company, valued at approximately $15,092,484. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, insider William Hait sold 14,698 shares of the company’s stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the sale, the insider now owns 87,747 shares of the company’s stock, valued at $15,092,484. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the transaction, the vice president now directly owns 102,696 shares of the company’s stock, valued at $17,491,182.72. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by company insiders.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- Pros And Cons Of Monthly Dividend Stocks
- 3 Reasons This Sleeping Giant Is About To Wake Up
- What Does Downgrade Mean in Investing?
- MarketBeat Week in Review – 9/18 – 9/22
- What is Put Option Volume?
- 52-week Low Names To Tip The Upside Scale In Your Favor
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
